Report: Oxford COVID-19 vaccine early trial shows positive result
The COVID-19 vaccine candidate produced by the University of Oxford along with AstraZeneca Plc showed promising results in early human testing, the news agency Bloomberg reported.
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.
He said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.
The potential vaccine is already in large-scale phase III human trials to assess whether it can protect against COVID-19. In phase-3, it will be tested on roughly 30,000 people in the US alone.
“We are working on the AstraZeneca Oxford vaccine which is undergoing phase III clinical trials. Besides, we will also start human trials in India in August 2020.
Based on the current situation and most recent updates on the clinical trials, we are hoping that the AstraZeneca Oxford vaccine will be available towards the end of 2020,” Serum Institute of India CEO Adar Poonawalla told news agency PTI.